Andrew M. Kaunitz
Abstract
The American Society of Clinical Oncology recommends that aromatase inhibitors be used as adjuvant therapy in women with hormone-receptor–positive
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The American Society of Clinical Oncology recommends that aromatase inhibitors be used as adjuvant therapy in women with hormone-receptor–positive
Key concepts: Medicine, Letrozole, Tamoxifen, Breast cancer, Oncology, Internal medicine, Cancer, Gynecology